3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Melanoma
146
Carcinoma, Non-Small-Cell Lung
112
Carcinoma, Renal Cell
74
Neoplasm Metastasis
53
Carcinoma, Hepatocellular
51
Squamous Cell Carcinoma of Head and Neck
50
Lung Neoplasms
48
Colorectal Neoplasms
34
Pancreatic Neoplasms
30
Neoplasms
30
Hodgkin Disease
30
Urinary Bladder Neoplasms
24
Sarcoma
23
Brain Neoplasms
23
Stomach Neoplasms
22
Head and Neck Neoplasms
21
Breast Neoplasms
21
Prostatic Neoplasms
20
Carcinoma, Transitional Cell
20
Glioblastoma
19
Recurrence
17
Colonic Neoplasms
17
Kidney Neoplasms
16
Uveal Melanoma
15
Small Cell Lung Carcinoma
15
Multiple Myeloma
15
Esophageal Neoplasms
15
Carcinoma, Squamous Cell
14
Skin Neoplasms
13
Leukemia, Myeloid, Acute
13
Interventions
Rituximab
5
fludarabine
4
Tacrolimus
4
Epoetin Alfa
4
Cyclophosphamide
4
Busulfan
4
Darbepoetin alfa
3
Alemtuzumab
3
fludarabine phosphate
2
entrectinib
2
atezolizumab
2
alectinib
2
Thiotepa
2
Therapeutics
2
Radiotherapy
2
Peripheral Blood Stem Cell Transplantation
2
Mycophenolic Acid
2
Methotrexate
2
Etoposide
2
Early Intervention, Educational
2
Cytarabine
2
Bortezomib
2
Antilymphocyte Serum
2
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
2
venetoclax
1
trametinib
1
tirbanibulin
1
sargramostim
1
plerixafor
1
phenethyl isothiocyanate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Lymphoproliferative Disorders
×
Nivolumab
×
Clear all
NCT02973113
2021-07-21
PREVALE
Baylor College of Medicine
Phase 1
Completed
8 enrolled